<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731234</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_RI-CHOP</org_study_id>
    <nct_id>NCT03731234</nct_id>
  </id_info>
  <brief_title>Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance</brief_title>
  <official_title>Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, single arm, phase II trial in patients with ≥ 18 and &lt;80
      years with poor-prognosis (IPI ≥ 2) and newly diagnosed ABC-DLBCL.

      Aim of the study is to assess the efficacy and the safety of R-CHOP in combination with
      ibrutinib for 6 cycles followed by ibrutinib maintenance for 18 months in ABC-DLBCL patients
      achieving at least a PR after the induction phase
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Step 1 - Screening phase If central review will confirm and define the diagnosis of ABC-DLBCL
      according the COO, eligible patients will have to sign an additional informed consent prior
      to receive the study subsequent treatment.

      Step 2 - study treatment phases Induction phase: 5 courses of R-CHOP every 21 days combined
      with ibrutinib (560 mg/day, continuously).

      Maintenance phase: patients achieving a CR or a PR after 5 courses of RI-CHOP21 will enter
      the maintenance phase with ibrutinib (560 mg/day, continuously) for 18 months.

      Radiotherapy could be delivered as consolidation treatment at the end of R-chemotherapy,
      according to Institution local clinical practice, in patients with focal PET positive
      residual disease and to bone extranodal lesions or scrotum, if testicular involvement
      irrespective of initial tumor diameter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (1st time point of assessment)</measure>
    <time_frame>Time between the date of enrolment and the date of disease progression, relapse or death from any cause (24 months)</time_frame>
    <description>PFS of the high/high-intermediate risk patients from date of enrolment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (2nd time point of assessment)</measure>
    <time_frame>Time between the date of enrolment and the date of disease progression, relapse or death from any cause (36 months)</time_frame>
    <description>PFS of the high/high-intermediate risk patients from date of enrolment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (3dr time point of assessment)</measure>
    <time_frame>Time between the date of enrolment and the date of disease progression, relapse or death from any cause (48 months)</time_frame>
    <description>PFS of the high/high-intermediate risk patients from date of enrolment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time between the date of enrolment and the date of death from any cause (24, 36 and 48 months).</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response and Overall Response (CR+PR) rate at the end of induction</measure>
    <time_frame>End of induction (EOI) (4 months)</time_frame>
    <description>Complete response and Overall Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From the date when criteria for response are met (CR or PR) until the date of progression or relapse. Patients without relapse or progression or death from other causes will be censored at their last assessment date (24 months from response date)</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CRR) after ibrutinib maintenance</measure>
    <time_frame>End of treatment (EOT) (up to 24 months)</time_frame>
    <description>Complete remission after ibrutinib maintenance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>From the date of enrolment to the date of disease progression, relapse from CR, initiation of subsequent systemic anti-lymphoma therapy after the least 6 cycles of RI-CHOP (each cycle is 21 days), or death whichever occurs first (24, 36 and 48 months)</time_frame>
    <description>Event Free Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Ibrutinib+R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance</description>
    <arm_group_label>Ibrutinib+R-CHOP</arm_group_label>
    <other_name>IMBRUVICA (commercial name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Histologically confirmed DLBCL not otherwise specified (NOS)

          -  ABC type defined by Lymph2Cx on the NanoString platform. Note: A formalin fixed
             paraffin embedded lymph node or tumor biopsy specimen must be submitted to Central
             Pathology for review during the Screening Period. The specimen must have been acquired
             by a surgical incision or excision biopsy or from a core needle biopsy

          -  Previously untreated disease

          -  Age ≥ 18 and &lt; 65 years

          -  IPI score ≥ 2

          -  Ann Arbor stage II-IV disease

          -  Measurable disease ≥ 1.5 cm in longest diameter, and measurable in 2 perpendicular
             dimensions

          -  Normal blood count as defined as: absolute neutrophil count ≥1.0 × 10 9 /L independent
             of growth factor support, platelet count ≥ 100,000/mm 3 or ≥ 50,000/mm 3 if bone
             marrow (BM) involvement independent of transfusion support in either situation Normal
             organ functions defined as: creatinine ≤2 times the upper limit of normal (ULN) or
             estimated Glomerular Filtration Rate (Cockroft-Gault) ≥40 ml/min/1.73m 2 , aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) ≤3× the ULN; total bilirubin
             ≤ 1.5 × the ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic
             origin: patients with documented Gilbert disease may be enrolled if total bilirubin is
             ≤ 3.0 × the ULN; International normalized ratio (INR) &lt; 1.5 × the ULN in the absence
             of therapeutic anticoagulation; partial thromboplastin time (PTT) or activated partial
             thromboplastin time (aPTT) &lt; 1.5 × the ULN in the absence of a lupus anticoagulant

          -  Patients with occult or prior hepatitis B infection (defined as HBsAg negative,
             anti-HBs positive and /or anti-HBc positive) may be included if hepatitis B virus
             (HBV) DNA is undetectable. These patients must be willing to undergo bi-monthly DNA
             testing and they should receive prophylaxis with Lamivudine

          -  No active hepatitis C virus (HCV) infection

          -  Known availability of biopsy material

          -  No Central Nervous System (CNS) disease (meningeal and/or brain involvement by
             lymphoma)

          -  Absence of active infections

          -  No peripheral neuropathy or active neurological non-neoplastic disease of CNS

          -  No major surgical intervention prior 3 months to enrolment if not due to lymphoma
             and/or no other disease life-threatening that can compromise chemotherapy treatment

          -  Patient with a history of curatively treated basal or squamous cell carcinoma or
             melanoma of the skin or in situ carcinoma of the cervix at any time prior to the
             study.

          -  Patients with any other malignancy that has been treated with surgery alone with
             curative intent and the malignancy has been in remission without treatment for at
             least 5 years prior to enrolment.

          -  Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in clinical trials. - Women of childbearing potential must have a
             negative serum (beta-human chorionic gonadotropin [Beta-hCG]) or urine pregnancy test
             at Screening. Women who are pregnant or breastfeeding are ineligible for this study.

          -  Life expectancy &gt; 6 months

        EXCLUSION CRITERIA

          -  DLBCL including High grade B-cell Lymphomas, both with double hit and NOS according to
             the 2017 Revised WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues

          -  GCB-DLBCL after centralized COO profiling

          -  Any other histologies than DLBCL: composite or transformed disease, patients with
             follicular lymphoma IIIB and large B-cell lymphoma with IRF4 rearrangement.

          -  Primary mediastinal lymphoma (PMBL)

          -  Known central nervous system lymphoma

          -  Primary testicular lymphoma

          -  Any prior lymphoma therapy

          -  Contraindication to any drug in the chemotherapy regimen

          -  Left ventricular ejection fraction (LVEF) &lt; 50%

          -  Neuropathy ≥ grade 2

          -  Seropositive for or active viral infection with HBV

          -  HBsAg positive

          -  HBsAg negative, anti-HBs positive and/or anti-HBc positive with detectable viral DNA

          -  Known seropositive active HCV

          -  Human immunodeficiency virus (HIV) infection

          -  Any of the following abnormal laboratory values (unless any of these abnormalities are
             due to underlying lymphoma): creatinine ≥ 2 times the ULN (unless creatinine clearance
             normal, or calculated creatinine clearance &lt; 40 mL/min (using the Cockcroft-Gault
             formula); AST or ALT ≥3 × the ULN; total bilirubin &gt;1.5 × the ULN: patients with
             documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN; INR
             &gt; 1.5 × the ULN in the absence of therapeutic anticoagulation; PTT or aPTT &gt; 1.5 × the
             ULN in the absence of a lupus anticoagulant&quot;

          -  History of stroke or intracranial hemorrhage within the past 6 months.

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists

          -  Requires treatment with strong CYP3A inhibitors

          -  History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification.

          -  Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics

          -  Major surgical intervention prior 4 weeks to enrollment if not due to lymphoma and/or
             other disease life-threatening that can compromise chemotherapy treatment

          -  Prior malignancies other than lymphoma in the last 5 years with exception of currently
             treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma
             of the cervix

          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
             risk.

          -  If female, the patient is pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Martelli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Medicina Traslazionale e di Precisione, Università 'La Sapienza'</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maurizio Martelli, Prof</last_name>
    <phone>00390649974779</phone>
    <email>martelli@bce.uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuela Zanni, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>manuela.zanni@ospedale.al.it</email>
    </contact_backup>
    <investigator>
      <last_name>Manuela Zanni, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche- Clinica di Ematologia</name>
      <address>
        <city>Ancona</city>
        <zip>60121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Gini, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>guido.gini@ospedaliriuniti.marche.it</email>
    </contact_backup>
    <investigator>
      <last_name>Guido Gini, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico- S.O.C. Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Spina, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>mspina@cro.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Spina, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia</name>
      <address>
        <city>Bari</city>
        <zip>70121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Attilio Guarini, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>attilioguarini@oncologico.bari.it</email>
    </contact_backup>
    <investigator>
      <last_name>Attilio Guarini, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi - Istituto di Ematologia &quot;Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <zip>40121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>pierluigi.zinzani@unibo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Pier Luigi Zinzani, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micheal Mian, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>micheal.mian@asbz.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Mian, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia - Ematologia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>alessandra.tucci@asst-spedalicivili.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandra Tucci, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco - SC Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Giuseppina Cabras, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Giuseppina Cabras, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ugo Consoli, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>ugo.consoli@tin.it</email>
    </contact_backup>
    <investigator>
      <last_name>Ugo Consoli, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Cosenza - UOC Ematologia</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Gentile, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>massimogentile@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Gentile, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetta Puccini, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>benedettapuccini@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Benedetta Puccini, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Ghiggi, MD</last_name>
    </contact>
    <contact_backup>
      <email>chiara.ghiggi@hsanmartino.it</email>
    </contact_backup>
    <investigator>
      <last_name>Chiara Ghiggi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donato Mannina, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>donamanni@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donato Mannina, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andres Ferreri, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>andres.ferreri@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andres Ferreri, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Corradini, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>paolo.corradini@unimi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Paolo Corradini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IEO Istitito Europeo di Oncologia - Divisione Ematoncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tarella, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>corrado.tarella@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Corrado Tarella, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Ravano, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>emanuele.ravano@ospedaleniguarda.it</email>
    </contact_backup>
    <investigator>
      <last_name>Emanuele Ravano, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena - Ematologia</name>
      <address>
        <city>Modena</city>
        <zip>41123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanna Leonardi, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>leonardi.giovanna@policlinico.mo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanna Leonardi, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - UOC Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pinto, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>apinto.int.napoli@tin.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Pinto, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>gaidano@med.uniupo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Gianluca Gaidano, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Padova - Ematologia</name>
      <address>
        <city>Padova</city>
        <zip>35121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Piazza, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>francesco.piazza@unipd.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Piazza, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Arcaini, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>luca.arcaini@unipv.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luca Arcaini, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia - Ematologia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Flenghi, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>flenghi@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Leonardo Flenghi, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>f.angrilli54@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Angrilli, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto - U.O.Ematologia</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Arcari, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>a.arcari@ausl.pc.it</email>
    </contact_backup>
    <investigator>
      <last_name>Annalisa Arcari, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Pisana - U.O. Ematologia</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Petrini, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>mario.petrini@med.unipi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Petrini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R. &quot;San Carlo&quot; - U.O. Ematologia</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Cimminiello, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>miki-doc@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Cimminiello, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Croci - Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani, MD</last_name>
    </contact>
    <contact_backup>
      <email>monica.tani@auslromagna.it</email>
    </contact_backup>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia -</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>merli.francesco@ausl.re.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Merli, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini - U.O. di Ematologia</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lia Molinari, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>annalia.molinari@auslromagna.it</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Lia Molinari, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Sant'Andrea - Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00183</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Tafuri, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>agostino.tafuri@ospedalesantandrea.it</email>
    </contact_backup>
    <investigator>
      <last_name>Agostino Tafuri, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Traslazionale e di Precisione, Università 'La Sapienza'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Martelli, Prof</last_name>
    </contact>
    <contact_backup>
      <email>martelli@bce.uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Maurizio Martelli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Camillo - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Battistina, MD</last_name>
    </contact>
    <contact_backup>
      <email>rbattistini@scamilloforlanini.rm.it</email>
    </contact_backup>
    <investigator>
      <last_name>Roberta Battistini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica S. Cuore - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Hohaus, Prof</last_name>
    </contact>
    <contact_backup>
      <email>stefan.hohaus@Unicatt.it</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas - U.O. Ematologia</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Balzarotti, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>monica.balzarotti@carcercenter.humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Monica Balzarotti, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza - UO Ematologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, MD</last_name>
    </contact>
    <contact_backup>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni - S.C. Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, Prof</last_name>
    </contact>
    <contact_backup>
      <email>marina.liberati@unipg.it</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Marina Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - Centro Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federica Cavallo, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>f.cavallo@unito.it</email>
    </contact_backup>
    <investigator>
      <last_name>Federica Cavallo, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Chiappella, Dott.ssa</last_name>
    </contact>
    <contact_backup>
      <email>achiappella@cittadellasalute.to.it</email>
    </contact_backup>
    <investigator>
      <last_name>Annalisa Chiappella, Dott.ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. C. Panico - U.O.C Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact_backup>
    <investigator>
      <last_name>Vincenzo Pavone, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata Trieste (ASUITS) SC Ematologia</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Zaja, Prof</last_name>
    </contact>
    <contact_backup>
      <email>francesco.zaja@asuits.sanita.fvg.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Zaja, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine)-SOC Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacopo Olivieri, Dott.</last_name>
    </contact>
    <contact_backup>
      <email>jacopo.olivieri@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Jacopo Olivieri, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo U.O.C Ematologia</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Merli, MD</last_name>
    </contact>
    <contact_backup>
      <email>michelepavia@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Activated-B-Cell DLBCL</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

